Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib + Bevacizumab Maintenance in BRCA Wild-type Advanced Ovarian Cancer
NCT06063070Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluzoparib in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by Sun Yat-sen University. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
fluzoparib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT06063070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06063070.